Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Director · CEO | March 16, 2024 | March 26, 2024 |
| EyePoint, Inc.EYPT · Entity 5702 | Director | August 18, 2026 | August 18, 2026 |
| VIVEVE MEDICAL, INC.VIVE · Entity 11899 | Director | November 26, 2019 | November 27, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date March 16, 2024 · Filed March 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,157,593 |
Reported balance
After 2024-03-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-03-16 · Exercise / conversion · Acquired 84,847 · Balance 1,157,593 F1: This reflects the number of restricted stock units that became vested as of March 16, 2024 .. |
| Common StockSEC Table I · non-derivative | Direct | 1,124,565 |
Reported balance
After 2024-03-21 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-03-21 · Sale · Disposed 33,028 · Balance 1,124,565 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Common StockSEC Table I · non-derivative | Direct | 1,137,065 |
Reported balance
After 2024-03-16 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2024-03-16 · Exercise / conversion · Acquired 12,500 · Balance 1,137,065 F1: This reflects the number of restricted stock units that became vested as of March 16, 2024 .. |
| Common StockSEC Table I · non-derivative | Direct | 1,133,979 |
Reported balance
After 2024-03-21 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2024-03-21 · Sale · Disposed 3,086 · Balance 1,133,979 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Common StockSEC Table I · non-derivative | Direct | 1,146,954 |
Reported balance
After 2024-03-16 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2024-03-16 · Exercise / conversion · Acquired 12,975 · Balance 1,146,954 F1: This reflects the number of restricted stock units that became vested as of March 16, 2024 .. |
| Common StockSEC Table I · non-derivative | Direct | 1,143,788 |
Reported balance
After 2024-03-21 transaction · row 6
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 6 · 2024-03-21 · Sale · Disposed 3,166 · Balance 1,143,788 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 84,847 |
Reported balance
After 2024-03-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-03-16 · Exercise / conversion · Disposed 84,847 · Balance 84,847 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,500 |
Reported balance
After 2024-03-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-03-16 · Exercise / conversion · Disposed 12,500 · Balance 12,500 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-03-16 · Exercise / conversion · Disposed 12,975 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F6: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units that became vested as of March 16, 2024 ..
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F4: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F6: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
EyePoint, Inc.
Report date August 18, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,100 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Purchase · Acquired 10,600 · Balance 49,100 |
VIVEVE MEDICAL, INC.
Report date November 26, 2019 · Filed November 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2029-11-25 | Direct | 330,000 |
Reported balance
After 2019-11-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-26 · Grant · Acquired 330,000 · Balance 330,000 F1: The stock option shall vest and become exercisable in 48 equal monthly installments after November 26, 2019, subject to the Reporting Person's continuous service to the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest and become exercisable in 48 equal monthly installments after November 26, 2019, subject to the Reporting Person's continuous service to the Issuer through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 18, 2026 20:08 UTC | EyePoint, Inc. EYPT · Entity 5702 | PurchaseCommon Stock | 10,600 | $4.93 | $52,258.00 |
DisclosureSEC source: 0001530968-26-000004 · primarydocument.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,100 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:09 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001530968-26-000002 · primarydocument.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-02 Read SEC document |
| July 11, 2025 Filed Jul 11, 2025 20:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005391 · primarydocument.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning July 11, 2023. F1 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning July 11, 2023. Read SEC document |
| July 11, 2025 Filed Jul 11, 2025 20:07 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005391 · primarydocument.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2025 Filed May 19, 2025 20:06 UTC | EyePoint, Inc. EYPT · Entity 5702 | PurchaseCommon Stock | 5,000 | $5.99 | $29,950.00 |
DisclosureSEC source: 0001562180-25-003997 · primarydocument.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,500 Read SEC document |
| May 16, 2025 Filed May 19, 2025 20:06 UTC | EyePoint, Inc. EYPT · Entity 5702 | PurchaseCommon Stock | 5,000 | $5.81 | $29,050.00 |
DisclosureSEC source: 0001562180-25-003997 · primarydocument.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,500 Read SEC document |
| May 15, 2025 Filed May 15, 2025 20:06 UTC | EyePoint, Inc. EYPT · Entity 5702 | PurchaseCommon Stock | 5,000 | $5.47 | $27,350.00 |
DisclosureSEC source: 0001562180-25-003873 · primarydocument.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,500 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.45 to $5.48. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:06 UTC | EyePoint, Inc. EYPT · Entity 5702 | PurchaseCommon Stock | 5,000 | $5.42 | $27,100.00 |
DisclosureSEC source: 0001562180-25-003873 · primarydocument.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.41 to $5.42. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:05 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000234 · primarydocument.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-03 Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:01 UTC | EyePoint, Inc. EYPT · Entity 5702 | PurchaseCommon Stock | 12,500 | $7.98 | $99,750.00 |
DisclosureSEC source: 0001562180-24-006431 · primarydocument.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.90 to $8.13. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 11, 2024 Filed Jul 12, 2024 21:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005698 · primarydocument.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning July 11, 2023. F1 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning July 11, 2023. Read SEC document |
| July 11, 2024 Filed Jul 12, 2024 21:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005698 · primarydocument.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 01:43 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 3,166 | $7.68 | $24,314.88 |
DisclosureSEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · nonDerivative · entry 6 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,143,788 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 01:43 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 3,086 | $7.68 | $23,700.48 |
DisclosureSEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · nonDerivative · entry 4 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,133,979 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 01:43 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 33,028 | $7.68 | $253,655.04 |
DisclosureSEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,124,565 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:43 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 12,975 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · derivative · entry 9 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,975 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:43 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · derivative · entry 8 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:43 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 84,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · derivative · entry 7 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,847 Underlying: Common Stock · 84,847 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:43 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 12,975 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · nonDerivative · entry 5 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,146,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024 .. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:43 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · nonDerivative · entry 3 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,137,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024 .. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:43 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 84,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000051 · wk-form4_1711417407.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,157,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024 .. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 02:12 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 25,014 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000401 · primarydocument.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,014 Underlying: Common Stock · 25,014 shares Expires 2034-01-04 Read SEC document |
| July 18, 2023 Filed Oct 14, 2023 00:27 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 22,076 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000135 · wk-form4_1697243235.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,072,746 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 22:51 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005879 · primarydocument.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning July 11, 2023. F1 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning July 11, 2023. Read SEC document |
| July 11, 2023 Filed Jul 12, 2023 22:51 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005879 · primarydocument.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 13:18 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001562180-23-005446 · primarydocument.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2033-06-19 Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 13:18 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 26,100 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-23-005446 · primarydocument.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,100 Underlying: Common Stock · 26,100 shares Expires 2033-06-19 Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:06 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 112,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000028 · wf-form4_167936076066059.xml · derivative · entry 6 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:06 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 179,000 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0000805928-23-000028 · wf-form4_167936076066059.xml · derivative · entry 5 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,000 Underlying: Common Stock · 179,000 shares Expires 2033-03-16 F5 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 12,975 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000028 · wf-form4_167936076066059.xml · derivative · entry 4 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,975 Underlying: Common Stock · 12,975 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000028 · wf-form4_167936076066059.xml · derivative · entry 3 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 12,975 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000028 · wf-form4_167936076066059.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,050,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2023. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:06 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000028 · wf-form4_167936076066059.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,037,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2023. Read SEC document |
| December 27, 2022 Filed Dec 30, 2022 01:35 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000135 · wf-form4_167236411526391.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Read SEC document |
| December 27, 2022 Filed Dec 30, 2022 01:35 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000135 · wf-form4_167236411526391.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This reflects the number of restricted stock units that vested on December 27, 2022. Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 21:51 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 26,746 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0000805928-22-000131 · wf-form4_167122742992025.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,746 shares Expires 2022-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 21:51 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 26,746 | $5.09 | $136,137.14 |
DisclosureSEC source: 0000805928-22-000131 · wf-form4_167122742992025.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 19:53 UTC | Axogen, Inc. AXGN · Entity 4297 | Disposition to issuerCommon Stock | 9,081 | $8.40 | $76,280.40 |
DisclosureSEC source: 0000805928-22-000086 · wf-form4_165834680588166.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 981,549 F2 · shares: The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on July 19, 2022. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 19:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 22,076 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000086 · wf-form4_165834680588166.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 988,409 F1 · shares: This reflects the number of shares that vested as of July 18, 2022 upon the attainment of certain performance criteria. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 20:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001562180-22-005662 · primarydocument.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2032-07-10 F2 · derivative.exercise_date: The option becomes exercisable in three ratable annual installments beginning on July 11, 2023. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 20:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005662 · primarydocument.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning July 11, 2023. F1 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning July 11, 2023. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:12 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 317,185 | $0.00 Strike: $10.25 | $0.00 |
DisclosureSEC source: 0000805928-22-000035 · wf-form4_164763430465185.xml · derivative · entry 4 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,185 Underlying: Common Stock · 317,185 shares Expires 2032-03-16 F5 · derivative.exercise_price: The exercise price of $10.25 represents a 25% premium over the fair market value of Axogen common stock on the date of the grant. F6 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 16, 2023 and on each anniversary thereafter. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:12 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 169,694 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000035 · wf-form4_164763430465185.xml · derivative · entry 3 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,694 Underlying: Common Stock · 169,694 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:12 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 25,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000035 · wf-form4_164763430465185.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,950 Underlying: Common Stock · 25,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:12 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 25,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000035 · wf-form4_164763430465185.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 966,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:14 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 13,978 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000015 · wf-form4_164513242186330.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 940,383 F1 · shares: This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria. F2 · balance_after: Includes 728 shares acquired under the Axogen stock purchase plan on December 31, 2021. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:33 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000185 · wf-form4_164081358767730.xml · derivative · entry 3 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 8,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:33 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,752 | $9.74 | $17,064.48 |
DisclosureSEC source: 0000805928-21-000185 · wf-form4_164081358767730.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 925,677 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:33 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000185 · wf-form4_164081358767730.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 927,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on December 27, 2021. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000177 · wf-form4_164020733379564.xml · derivative · entry 3 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.